Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Adjuvant chemotherapy in rectal cancers: why a standard in the US and not in Europe?

Nature Clinical Practice Oncology volume 1, pages 58–59 (2004)Cite this article

In 1990, a US National Institutes of Health (NIH) Consensus Conference recommended postoperative chemoradiotherapy as standard treatment for stage II and III rectal cancer.1 The recommendations mean that, unless medical or psychosocial contraindications to treatment are present, patients should postoperatively receive 5-FU-based chemotherapy for about 6 months together with 5 to 6 weeks of radiation. The recommendations were further emphasized in an NCI Clinical Announcement in 1991 and since then repeatedly in many textbooks, reviews and in Patterns of Care studies.2 Even though there is a trend in the US to use more preoperative radiotherapy, particularly if sphincter preservation can be increased, adjuvant chemotherapy is the standard of care for rectal cancer in the US, although not uniformly adopted after preoperative radiochemotherapy.2,3 However, in a presently ongoing US Intergroup trial, E3201, rectal cancer patients who receive preoperative radiochemotherapy are all randomized to one of three chemotherapy regimens postoperatively. Since a response to the preoperative treatment greatly influences postoperative outcome, the choice of whether to give adjuvant chemotherapy and the type of adjuvant treatment ought to be influenced by whether or not a response was seen.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444–1450

  2. Minsky BD et al. (1998) Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. Int J Radiat Oncol Biol Phys 41: 21–27

    Article  CAS  Google Scholar 

  3. Minsky BD (2003) Adjuvant therapy for rectal cancer—the transatlantic view. Colorectal Dis 5: 416–422

    Article  CAS  Google Scholar 

  4. Mansour EG et al. (1991) A comparison of postoperative adjuvant chemotherapy, radiotherapy or combination therapy in potentially curable resectable rectal carcinoma. An ECOG study Est 4276. [abstract] Proc Am Soc Clin Oncol 10: 154

    Google Scholar 

  5. Glimelius B (2001) Chemoradiotherapy for rectal cancer – is there an optimal combination? Ann Oncol 12: 1039–1045

    Article  CAS  Google Scholar 

  6. Glimelius B et al. (2003) A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 42: 476–492

    Article  Google Scholar 

  7. Ragnhammar P et al. (2001) A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40: 282–308

    Article  CAS  Google Scholar 

  8. Taal BG et al. (2001) Adjuvant 5-FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 85: 1437–1443

    Article  CAS  Google Scholar 

  9. Elsaleh H et al. (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745–1750

    Article  CAS  Google Scholar 

  10. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer (2004) Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22: 484–492

  11. Bosset JF et al. (2004) Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer: Report of the 22921 EORTC phase III trial. [abstract] Proc Am Soc Clin Oncol 22: a3504

    Article  Google Scholar 

  12. Conroy T et al. (2004) Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial. [abstract] Proc Am Soc Clin Oncol 22: a3626

    Article  Google Scholar 

  13. Glimelius B (2002) Has progress been made in gastrointestinal cancer treatment? Acta Oncol 41: 115–117

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professor, Department of Oncology, Uppsala and Department of Oncology and Pathology, Radiology and Clinical Immunology, University Hospital, Karolinska University Hospital, Stockholm, Sweden

    Bengt Glimelius

Authors
  1. Bengt Glimelius
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bengt Glimelius.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Glimelius, B. Adjuvant chemotherapy in rectal cancers: why a standard in the US and not in Europe?. Nat Rev Clin Oncol 1, 58–59 (2004). https://doi.org/10.1038/ncponc0042

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0042

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing